192050-59-2

Usage

Uses

Used in Pharmaceutical Industry:
(9S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione methanesulfonate is used as a potent drug or pharmaceutical compound for its potential interactions with biological systems due to its complex structure and the presence of a dimethylamino group.
Used in Drug Formulation:
In the pharmaceutical industry, (9S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione methanesulfonate is used as a salt form to improve the solubility and stability of the compound, which is essential for effective drug delivery and formulation.

Upstream product

• 75-75-2 methanesulfonic acid 
• 169940-46-9 (9S)-6,7,10,11-tetrahydro-9-{[(methylsulfonyl)oxy]methyl}-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]-oxadiazacyclohexadecine-18,20(19H)-dione 
• 169940-55-0 (9S)-6,7,10,11-tetrahydro-9-(hydroxymethyl)-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13 ]-oxadiazacyclohexadecine-18,20(19H)-dione 
• 170277-76-6 (9S)-6,7,10,11-tetrahydro-9-[(triphenylmethoxy)methyl]-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]-oxadiazacyclohexadecine-18,20(19H)-dione 
• 170277-75-5 (9S)-6,7,10,11-tetrahydro-9-[(triphenylmethoxy)methyl]-5,21:12,17-dimetheno-9H-dibenzo[e,k]furo[3,4-h][1,4,13]-oxadiazacyclohexadecine-18,20-dione 
• 170277-74-4 (9S)-6,7,10,11-tetrahydro-19-methyl-9-[(triphenylmethoxy)-methyl]-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h]-[1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione 
• 113963-68-1 bisindolylmaleimide V 

Relevant academic research and scientific papers

Synthesis and Characterization of the Selective, Reversible PKCβ Inhibitor (9 S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9 H,18 H-5,21:12,17-dimethenodibenzo[ e,k]pyrrolo[3,4- h][1,4,13]oxadiazacyclohexadecine-18,20(19 H)-dione, Ruboxistaurin (LY333531)

The demonstrated role of PKCβ in mediating amphetamine-stimulated dopamine efflux, which regulates amphetamine-induced dopamine transporter trafficking and activity, has promoted the research use of the selective, reversible PKCβ inhibitor (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione, ruboxistaurin. Despite the interest in development of ruboxistaurin as the mesylate monohydrate (Arxxant) for the treatment of diabetic retinopathy, macular edema, and nephoropathy, several crucial details in physicochemical characterization were erroneous or missing. This report describes the synthesis and full characterization of ruboxistaurin free base (as a monohydrate), including X-ray crystallography to confirm the absolute configuration, and of the mesylate salt, isolated as a hydrate containing 1.5 mol of water per mole.